Use of Off-Label Drugs and Nutrition Supplements among Patients with Amyotrophic Lateral Sclerosis in Norway

Table 1

Patients reporting off-label use of medications against ALS.

Medication	n (%)^†
Low-dose naltrexone	8 (19.5)
Drug studies (NO-ALS)^‡,§	7 (17.7)
Dextromethorphan hydrobromide/quinidine sulfate (Nudexta)	2 (4.9)
Ropinirol	1 (2.4)
Metformin	1 (2.4)

^†Each respondent could report more than one medication; either by choosing predefined alternatives or give information as free text. ^‡The NO-ALS study is a randomized placebo-controlled clinical intervention study of nicotinamide riboside/pterostilbene as a supplement in early ALS (clinicalTrials.gov ID: NCT04562831). ^§The NO-ALS study was the only study that respondents reported being part of and the only available drug study in Norway. It is not known whether respondents are in the intervention or placebo group.